Table 1 Characteristics of the included studies
From: Expression of CXCR4 and breast cancer prognosis: a systematic review and meta-analysis
Author | Year | Country | Number of patients | Duration of follow-up | Methods | Staining patterns | Cut off scores (high/low) | T category (T0/T1/2/3/4) | N category (P/N) | Distant metastasis (M1/M0) | State of CerbB-2 (P/N) | Stata of ER (P/N) | Stata of PR (P/N) | 5-year OS rate | 5-year DFS rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Zhang [10] | 2012 | China | 232 | NA | IHC | Membrane or cytoplasm | 5% (134/98) | H:(0/48/86/0/0); L:(0/38/60/0/0) | H:(70/64); L:(28/70) | NA | H:(82/52); L:(38/60) | H:(52/82); L:(44/54) | H:(44/90); L:(38/60) | Â | Â |
PARKER [11] | 2012 | USA | 185 | 54 months | Western blots | Membrane and cytoplasm | ≥7.5 F (37/148) | H:(0/7/21/7/2); L:(2/21/82/24/18) | H:(37/37); L:(148/148) | NA | H:(14/20); L:(39/91) | H:(12/23); L:(51/97) | H:(11/24); L:(45/103) | H:57% (21/37) L:69% (102/148) | H:53% (20/37) L:62% (92/148) |
Hiller [12] | 2011 | USA | 77 | 42 months | Western blots | Membrane and cytoplasm | ≥6.6 F (22/55) | LABC(NA) | NA | NA |  |  |  | H:50% (11/22) L:78% (43/55) | H:41% (9/22) L:67% (37/55) |
Chu [13] | 2010 | USA | 101 | 59 months | Western blots | Membrane and cytoplasm | ≥6.6 F (22/79) | H:(0/8/11/3/0); L:(0/58/18/3/0) | NA | NA |  |  |  | H:81% (18/22) L:97% (77/79) | H:79% (17/22) L:96% (76/79) |
Liu [14] | 2010 | China | 200 | 88 months | TMA | Cytoplasm | Score ≥ 6 (110/90) | H:(0/41/56/13/0); L:(0/27/50/13/0) | H:(69/41); L:(31/59) | NA | H:(32/78); L:(15/75) | H:(59/51); L:(41/49) | H:(60/50); L:(39/51) | H:68% (75/110) L:80% (72/90) |  |
Liu* [14] | 2010 | China | 200 | 88 months | TMA | Nuclear | Score ≥ 6 (113/87) | H:(0/32/67/14/0); L:(0/36/39/12/0) | H:(61/52); L:(39/48) | NA | H:(87/26); L:(21/66) | H:(62/51); L:(38/49) | H:(62/51); L:(37/50) | H:63% (71/113) L:82% (71/87) |  |
Mizell [15] | 2009 | USA | 115 | 53 months | Western blots | Membrane and cytoplasm | ≥6.6 F (13/102) | H:(0/2/10/0/1); L:(0/41/50/10/1) | H:(6/7); L:(31/71) | H:(5/8); L:(14/88) | H:(0/13); L:(0/102) | H:(2/11); L:(37/65) | H:(2/11); L:(34/68) | H:52% (7/13) L:86% (88/102) | H:38% (5/13); L:74% (75/102) |
ANDRE [16] | 2009 | USA | 794 | 10 years | IHC | Membrane or cytoplasm | 1% (92/702) | H:≥3 (9/81); L: ≥3 (61/637) | H:(40/51); L:(300/402) | H:(28/64); L:(155/547) | H:(10/79); L:(88/607) | H:(41/36); L:(378/238) |  |  |  |
Yasuoka [17] | 2008 | Japan | 113 | 5 years | IHC | Cytoplasmic | Score ≥ 5 (56/57) | T1:H:15; L: 19 T2-4:H:41; L: 28 | H:(36/20); L:(23/34) | H:(22/34); L:(7/50) | H:(19/39); L:(15/42) | H:(32/24); L:(36/21) | H:(29/27); L:(33/24) |  |  |
Yasuoka* [17] | 2008 | Japan | 113 | 5 years | IHC | Nuclear | Score ≥ 5 (29/84) | T1:H:11; L: 23 T2-4:H:18; L: 61 | H:(13/16); L:(46/38) | H:(7/22); L:(22/62) | H:(7/22); L:(25/59) | H:(18/11); L:(50/34) | H:(17/12); L:(45/39) |  |  |
Woo [18] | 2007 | Korea | 107 | NA | IHC | Cytoplasm | Score ≥ 4 (33/72) | H:(0/7/18/8/0); L:(0/19/45/8/0) | H:(21/12); L:(34/38) |  | H:(17/15); L:(30/34) | H:(20/13); L:(41/27) | H:(20/13); L:(38/28) |  |  |
Woo* [18] | 2007 | Korea | 107 | NA | IHC | Nuclear | Score ≥ 4 (63/42) | H:(0/16/37/10/0); L:(0/10/26/6/0) | H:(39/24); L:(16/26) |  | H:(31/28); L:(16/21) | H:(39/23); L:(22/17) | H:(36/24); L:(22/17) |  |  |
Holm [19] | 2007 | USA | 103 | 26 months | Western blots | Membrane and cytoplasm | ≥6.6 F (41/62) | H:(0/7/27/5/2); L:(0/23/32/7/0) | H:(23/17); L:(33/30) |  |  |  |  |  | H:46% (19/41); L:70% (43/62) |
Su [20] | 2006 | Taiwan | 85 | NA | IHC | Cytoplasm | Score ≥ 3 (10/75) | H:(0/2/8/0/0); L:(0/34/41/0/0) | H:(5/2); L:(21/41) | H:(1/9); L:(8/67) | H:(6/3); L:(38/25) | H:(7/3); L:(44/24) | H:(3/7); L:(41/27) |  |  |
Su* [20] | 2006 | Taiwan | 85 | NA | IHC | Nuclear | Score ≥ 3 (59/26) | H:(0/27/32/0/0); L:(0/9/17/0/0) | H:(15/30); L:(11/13) | H:(6/53); L:(3/23) | H:(30/19); L:(14/9) | H:(33/20); L:(18/7) | H:(29/24); L:(15/10) |  |  |
Salvucci [21] | 2006 | Canada | 1699 | 68 months | TMA | Cytoplasm | >50%, 30–50, <30 (121/590/986) |  | H:(40/66); M:(112/242); L:(422/460) |  | H:(108/705); M:(90/390) L:(32/57) | H:(63/58); M:(436/154) L:(807/179) | H:(19/102); M:(180/396); L:(359/597) |  |  |
Salvucci* [21] | 2006 | Canada | 1697 | 69Â months | TMA | Nuclear | 30% (1161/538) | Â | H:(514/527); L:(218/242) | Â | H:(160/809); L:(70/343) | H:(895/266); L:(412/126) | H:(390/743); L:(166/353) | Â | Â |
Holm [22] | 2009 | USA | 54 | 30 months | Western blots | Membrane and cytoplasm | ≥6.6 F (19/35) |  |  |  |  |  |  | H:15% (3/19) L:40% (14/35) | H:20% (4/19); L:55% (19/35) |